Aprea Therapeutics (APRE) investor relations material

Executive summary

• Focused on precision oncology, developing targeted therapies for biomarker-defined cancers using synthetic lethality approaches, with lead programs APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor).

• Closed an oversubscribed $30 million private placement to support ongoing development of APR-1051 and expand clinical enrollment.

• Phase 1 clinical data for APR-1051 showed promising partial responses in uterine serous carcinoma and uterine carcinosarcoma, with favorable tolerability.

• Cash and cash equivalents totaled $46.5 million as of March 31, 2026, providing runway into Q1 2028.

• Net loss for Q1 2026 was $3.3 million, or $(0.22) per share, compared to $3.9 million, or $(0.66) per share, in Q1 2025.

Financial highlights

• Cash and cash equivalents increased to $46.5 million from $14.6 million at year-end 2025, reflecting private placements.

• Net loss for Q1 2026 was $3.3 million, an improvement from $3.9 million in Q1 2025, driven by lower R&D expenses.

• Research and development expenses decreased to $1.6 million from $2.5 million year-over-year, mainly due to the pause in ATRN-119 monotherapy trial.

• General and administrative expenses remained stable at $1.8 million.

• No grant revenue recognized in Q1 2026, compared to $0.2 million in Q1 2025.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2028 based on current plans.

• Anticipates increased expenses as clinical development progresses, especially for APR-1051 and combination studies for ATRN-119.

• Completion of dose escalation in the ACESOT-1051 trial is anticipated in Q2 2027.

• Further clinical updates from ACESOT-1051 are expected in Q2 2026, with data to be presented at ASCO 2026.

• No expectation of product revenue for several years; additional funding will be needed for long-term operations.